IP Library › Granted Patent US 11,260,002
Granted Patent B2
US 11,260,002 · App. 16/572,749 · Granted Mar 1, 2022

Oral care composition

Inventors: Michael Prencipe (West Windsor, NJ); Yun Xu (Langhorne, PA); Xiao Yi Huang (Guangzhou, CN)
Assignee: Colgate-Palmolive Company
A61K8/27A61K8/43A61K8/44A61Q11/00A61K2800/51
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,260,002
App. No.
16/572,749
Granted
Mar 1, 2022
Kind
B2
Abstract

An oral care composition comprising: (a) arginine, in free or salt form; and (b) zinc oxide and zinc citrate. The oral care composition can reduce or inhibit biofilm formation in an oral cavity.

Claims (15)

1. An oral care composition comprising:

a. arginine, in free or salt form, wherein the arginine is present in an amount of about 1.5%, based on the total weight of the composition and wherein the amount of the arginine in salt form is measured as the free base equivalent;

b. zinc oxide and zinc citrate, wherein the total concentration of zinc salts in the composition is 0.2 weight % to 5 weight %, based on the total weight of the composition; and

wherein a molar ratio of arginine to total zinc salts is 0.4:1 to 0.8:1, and wherein a weight ratio of zinc oxide to zinc citrate is 1.7:1 to 2.3:1.

2. The oral care composition of claim 1 , wherein the composition comprises zinc oxide in an amount of 0.5 weight % to 1.5 weight % and zinc citrate in an amount of 0.25 weight % to 0.75 weight %, based on the total weight of the composition.

3. The oral care composition of claim 2 , wherein the composition comprises zinc oxide in an amount of about 1 weight % and zinc citrate in an amount of about 0.5 weight %, based on the total weight of the composition.

4. An oral care composition according to claim 1 , for use in reducing or inhibiting biofilm formation in an oral cavity.

5. A method of reducing or inhibiting biofilm formation in an oral cavity, the method comprising contacting the oral cavity with an oral care composition according to claim 1 .

6. The method of claim 5 , wherein a weight ratio of zinc oxide to zinc citrate is about 2:1.

7. The method of claim 5 , wherein the zinc oxide is present in the oral care composition in an amount of 0.5 weight % to 1.5 weight % and the zinc citrate is present in the oral care composition in an amount of 0.25 weight % to 0.75 weight %, based on the total weight of the composition.

8. The method of claim 7 , wherein the zinc oxide is present in the oral care composition in an amount of about 1 weight % and the zinc citrate is present in the oral care composition in an amount of about 0.5 weight %, based on the total weight of the composition.

9. An oral care composition comprising:

a. arginine, in free or salt form, wherein the arginine is present in an amount of about 1.5%, based on the total weight of the composition, wherein the amount of the arginine in salt form is measured as the free base equivalent; and

b. zinc oxide and zinc citrate, wherein a molar ratio of arginine to total zinc salts is 0.4:1 to 0.8:1 and wherein a weight ratio of zinc oxide to zinc citrate is about 2:1.

10. The oral care composition of claim 9 , wherein the molar ratio of arginine to total zinc salts is about 0.65:1 and wherein the weight ratio of zinc oxide to zinc citrate is about 2:1.

Priority Claims (1)
CN 201310703017.9 · Dec 19, 2013 · national
Continuity (2)
Continuation 15106457
Related Publication 20200009031A1 · Jan 9, 2020